Perspective Therapeutics priced 39,576,088 shares at $3.79 each, plus pre-funded warrants for 6,598,046 shares, for gross proceeds of about $175 million. Piper Sandler & Co. is one of five joint book-running managers, and Hogan Lovells US LLP is counsel to the company.
Latest Perspective Therapeutics news
We have not published a story on Perspective Therapeutics yet. When there is news, it will appear here.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $48.5 million, plus short-term investments of $188.4 million, $236.9 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Perspective Therapeutics
Has Perspective Therapeutics raised money recently?
Our latest story on this, dated Feb 3, 2026: "Perspective Therapeutics prices $175 million stock and pre-funded warrant offering". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Perspective Therapeutics?
Perspective Therapeutics, Inc. trades under the ticker CATX on AMEX.
Where is Perspective Therapeutics listed?
Perspective Therapeutics, Inc. is listed on AMEX.
What is the SEC CIK of Perspective Therapeutics?
The SEC Central Index Key (CIK) for Perspective Therapeutics, Inc. is 728387. Its filings are on SEC EDGAR.
How many shares does Perspective Therapeutics have outstanding?
114,151,663 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-10.
Which country or territory is Perspective Therapeutics listed under?
Our directory records Perspective Therapeutics, Inc. under United States.
What does Perspective Therapeutics do?
Our directory classifies Perspective Therapeutics, Inc. as: Radiopharmaceuticals. This is a directory classification, not a description of the pipeline.
What is the ISIN of Perspective Therapeutics?
The ISIN recorded for Perspective Therapeutics, Inc. is US46489V3024.
Does aibio.space cover Perspective Therapeutics?
aibio.space lists Perspective Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Perspective Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
Is Perspective Therapeutics profitable?
Perspective Therapeutics, Inc. reported a net loss of $103.1 million for the fiscal year ended Dec 31, 2025, and used $82.5 million of cash in operations, per its annual report to the SEC.
How much does Perspective Therapeutics spend on research and development?
$84.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Perspective Therapeutics have?
$236.9 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Perspective Therapeutics (CATX) stock news?
Our latest story on Perspective Therapeutics, dated Feb 3, 2026: "Perspective Therapeutics prices $175 million stock and pre-funded warrant offering". Perspective Therapeutics priced 39,576,088 shares at $3.79 each, plus pre-funded warrants for 6,598,046 shares, for gross proceeds of about $175 million. Piper Sandler & Co. is one of five joint book-running managers, and Hogan Lovells US LLP is counsel to the company. Source.
What is Perspective Therapeutics's market cap?
We do not publish live share prices. In its annual report, Perspective Therapeutics, Inc. put the market value of shares held by non-affiliates (public float) at $212.9 million as of Jun 30, 2025.
Investor discussion: Perspective Therapeutics
Members talk about Perspective Therapeutics (CATX). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Perspective Therapeutics, newest first. Each line links the filing it comes from.
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open AMEX:CATX on TradingView.
SEC filings and registration
SEC name
Perspective Therapeutics, Inc.
CIK
728387
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
CATX (NYSE)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company
Business address
2401 ELLIOTT AVENUE, SEATTLE, WA, 98121
Phone
206-676-0900
Shares outstanding
114,151,663 as of 2026-08-05 (10-Q filed 2026-08-10)
Former names
IsoRay, Inc.; Isoray, Inc.; CENTURY PARK PICTURES CORP
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Perspective Therapeutics, Inc. is a public biotech or pharmaceutical company listed on AMEX under the ticker CATX, recorded under United States. The directory classifies it as Radiopharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio